Phd Position - Erlangen, Deutschland - Universitätsklinikum Erlangen

Universitätsklinikum Erlangen

Geprüftes Unternehmen

Erlangen, Deutschland

vor 3 Wochen

Geschrieben von:

Lena Wagner

beBee Recruiter

Beschreibung

Universitätsklinikum Erlangen
Experimental Renal and Cardiovascular Research of the Nephropathology Department, Institute of Pathology
Prof. Felix B. Engel
Schwabachanlage 12 (TRC)
91054 Erlangen

Ihre Ansprechperson bei Fragen

Prof. Felix B. Engel
PI

phone:

PhD position (m/w/d)

Veröffentlicht seit:

Job-Nr
:

5244

Ihre Ansprechperson bei Fragen

Prof. Felix B. Engel
PI

phone:

Anschrift

Universitätsklinikum Erlangen
Experimental Renal and Cardiovascular Research of the Nephropathology Department, Institute of Pathology
Prof. Felix B. Engel
Schwabachanlage 12 (TRC)
91054 Erlangen

mehr anzeigen

PhD position (m/w/d)

Veröffentlicht seit:

Job-Nr
:

5244
Universitätsklinikum Erlangen
Experimental Renal and Cardiovascular Research of the Nephropathology Department, Institute of Pathology
Prof. Felix B. Engel
Schwabachanlage 12 (TRC)
91054 Erlangen
Ihre Ansprechperson bei Fragen

Prof. Felix B. Engel
PI

phone:

Klingt spannend?

Das sind wir:

State-of-the-art medicine and nursing care you can rely on - Since being founded in 1815, Universitätsklinikum Erlangen has offered medicine of the highest standard and incorporated the latest insights from medical research and state-of-the-art equipment into diagnosis and therapy.

More than 9.500 employees from approximately 50 different occupations are needed to provide the wide range of services offered by Universitätsklinikum Erlangen, ensuring our patients receive the very best care around the clock.

The project is part of the Interdisciplinary Center for Clinical Research (IZKF, in collaboration with Markus Eckstein).

Project description:

Platinum-based chemotherapy, targeted chemotherapy and immune checkpoint inhibitors are approved for clinical handling of locally advanced (la) and metastatic (m) urothelial carcinoma (UC).

Yet, overall response rates for these therapies are limited (~20%), patients often progress rapidly, and molecular insights in processes driving therapy resistance are scarce.

TCGA data analysis suggests that fatty acid (FA) metabolism and ferroptosis are deregulated in UC contributing to chemoresistance. Overall aim of the here proposed project is to expand our already initiated living patient-derived laUC/mUC biobank to identify novel predictive biomarkers for laUC/mUC patients eligible for either chemo
- or immunotherapy as well as to utilize a high throughput zebrafish platform to elucidate mechanism underlying chemo
- and immunotherapy resistance and to predict therapy outcome.

Aim 1:

Expanding our existing patient-derived living laUC/mUC biobank and identification of predictive biomarkers in regards to therapy resistance

Aim 2:

Evaluating the therapeutic response of patient-derived UC cells in a zebrafish model

Aim 3:

Determining the effect of ferroptosis induction and/or FA metabolism alteration on UC treatment resistance utilizing a novel zebrafish model

Aim 4:

Assessing the role of potential biomarkers in chemo
- and immunotherapy resistance.

The Engel lab:

We are currently 3 postdocs, 5 PhD students, and 2 technicians plus some MD and Master students.

The lab is very international and interdisciplinary working on cancer biology, heart development and regeneration, biofabrication, as well as kidney development and disease utilizing molecular and cell biology techniques, biofabrication, zebrafish, mice, and rats as well as hiPSCs and human patient tissues.

Prof.

Engel has published > 100 manuscripts ( > 45 as senior author) in peer-reviewed scientific journals with > 5,650 total citations and an h-index of 42.

He published in a large variety of high impact factor (IF) journals as senior author (IF > 15: Cell Res, Adv Funct Mater), leading interdisciplinary journals (PNAS, Elife) as well as leading journals in the various research fields (Adv Healthc Mater, Biomaterials, Development, Cardiovasc Res).

In addition, the group is highly engaged in collaborations and contributed to publications in journals such as Cell, Mol Cell, Dev Cell, Curr Biol, and Biofabrication.

Die Aufgaben

Das Know-how dafür

Diplom or Master in Biology, Chemistry, Biochemistry, Moleculare Medicine, Bioinformatics or similar, very good English

Zusätzlich von Vorteil

Experience with zebrafish and/ or primary cell culture would be of advantage.

Das bieten wir

An interesting job in a motivated, open-minded team
Careful and qualified training
Comprehensive health promotion offers
Intended pay grade depending on qualifications and personal requirements according to TV-L E13
The position is limited in time (3 years)
It's a part-time position (65%)
The employment will take place at the earliest possible date

Arbeiten am UKER
Wir zählen zu den besten Krankenhäusern Deutschlands und sind einer der größten Arbeitgeber in Mittelfranken. Diesen Erfolg erarbeiten tagtäglich unsere über 9.500 hoch qualifizierten Beschäftigt